TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2680684

Group type: EXPERIMENTAL
Intervention: 20-sec continuous rattle sound
Number of subjects: 64

Group type: COMPARATOR
Intervention: 14-msec rattle sound
Number of subjects: 64

Group type: COMPARATOR
Intervention: 500-msec rattle sound
Number of subjects: 64

Group type: COMPARATOR
Intervention: 90 dB, 14-msec rattle sound
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 10-sec sound at 70 dB
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Trains of repeated 14-msec rattle sounds (2/sec, 1.3/sec, and 1/sec) lasting 10 sec
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 10-sec continuous rattle sound
Number of subjects: 64

Group type: COMPARATOR
Intervention: Slowly repeating sounds
Number of subjects: 64
Study: 920496

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide treatment for alcohol withdrawal
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low dose ethanol treatment for alcohol withdrawal
Number of subjects: 18

Group type: COMPARATOR
Intervention: Experimental alcoholization study (9 subjects)
Number of subjects: 18
Study: 31573666

Group type: EXPERIMENTAL
Intervention: Topical skin formulation PT1 (2 strains of C. acnes SLST type C3 and K8, 50% each)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Topical skin formulation PT2 (4 strains of C. acnes SLST type C3 [55%], K8 [5%], A5 [30%] and F4 [10%])
Number of subjects: 14

Group type: COMPARATOR
Intervention: 5% benzoyl peroxide gel (active induction phase, 7 days)
Number of subjects: 14
Study: 27550732

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 25218370

Group type: EXPERIMENTAL
Intervention: 1 STR and 1 ART
Number of subjects: 21

Group type: COMPARATOR
Intervention: 2 STRs
Number of subjects: 21

Group type: COMPARATOR
Intervention: 2 ARTs
Number of subjects: 21
Study: 22688258

Group type: EXPERIMENTAL
Intervention: 25mg hydrocortisone
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 22068184

Group type: EXPERIMENTAL
Intervention: Polished surfaces (test group)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Unpolished surfaces (control group)
Number of subjects: 76
Study: 19748761

Group type: EXPERIMENTAL
Intervention: Usual care plus NMES for four weeks (daily stimulation to both thighs for up to 30 minutes, frequency 50Hz, 'on' cycle 11%-25%)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Usual care plus NMES for four weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16
Study: 17013637

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (B/N) 8/2 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (B/N) 16/4 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (B/N) 32/8 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (double-blind)
Number of subjects: 8
Study: 15232046

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (12 weekly sessions)
Number of subjects: 17
Study: 11371692

Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg twice daily from 36‐38 weeks' gestation, 600 mg during labour, and 300 mg twice daily for 7 days post‐partum)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 407

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Maternal CD4 lymphocyte count < 200/mm3
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Child HIV‐1 infection
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Maternal death
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Diagnosis of paediatric infection on or before day 12
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Diagnosis of paediatric infection between days 13 and 45
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Clinical paediatric AIDS
Number of subjects: 407
Study: 9158849

Group type: EXPERIMENTAL
Intervention: Standardized single food meal
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Standardized mixed food meal
Number of subjects: 26

Group type: COMPARATOR
Intervention: Matched non-hyperphagic controls with dementia
Number of subjects: 26

Group type: COMPARATOR
Intervention: Matched normal elderly
Number of subjects: 26
Study: 7963189

Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 267

Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 267
Study: 3524797

Group type: EXPERIMENTAL
Intervention: Intermediate-dose methotrexate (IDM)
Number of subjects: 634

Group type: COMPARATOR
Intervention: Cranial irradiation (CRT) plus intrathecal methotrexate (MTX)
Number of subjects: 634
Study: 31629306

Group type: EXPERIMENTAL
Intervention: 25 g of amino acid mixture twice daily for 7 days
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no amino acid supplementation)
Number of subjects: 94
Study: 29141739

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (2.7 × 10^5 PfSPZ)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 30
Study: 27307526

Group type: EXPERIMENTAL
Intervention: Low dosage MTX (7.5 mg/week)
Number of subjects: 309

Group type: COMPARATOR
Intervention: High dosage MTX (20 mg/week)
Number of subjects: 309
Study: 25491622

Group type: EXPERIMENTAL
Intervention: Continuous blood purification in combination with ulinastatin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group treatment (oxygen inhalation, dynamic ECG monitoring, physical cooling methods)
Number of subjects: 40
Study: 23025303

Group type: EXPERIMENTAL
Intervention: Self-generated arguments about exercise
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Self-generated arguments about smoking cessation
Number of subjects: 183
Study: 20307600

Group type: EXPERIMENTAL
Intervention: Craving condition (participants abstained from eating chocolate for 24h prior to testing)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control condition (participants did not abstain from chocolate)
Number of subjects: 96
Study: 18650153

Group type: EXPERIMENTAL
Intervention: Ixabepilone 40 mg/m2 plus capecitabine 1650-2000 mg/m2 (schedule A)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ixabepilone 8-10 mg/m2 plus capecitabine 1650 mg/m2 (schedule B)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ixabepilone plus capecitabine (phase II)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Grade 3/4 treatment-related events in phase II
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Grade 3/4 neutropenia and leukopenia
Number of subjects: 106
Study: 16882128

Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate 6 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12514275

Group type: EXPERIMENTAL
Intervention: Beta-carotene (24 mg/d from an algal source)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Carotenoid mix (24 mg/d consisting of beta-carotene, lutein, and lycopene at 8 mg/d each)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10885881

Group type: EXPERIMENTAL
Intervention: Nickel exposure in mining sector
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nickel exposure in smelting sector
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nickel exposure in refining sector
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nickel exposure in milling sector
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Median rate of change in exposure levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Workplaces with no ventilation system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Groups of workers performing similar tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: North American workplaces
Number of subjects: 0
Study: 8622025

Group type: EXPERIMENTAL
Intervention: Taxol (paclitaxel) at a starting dose of 170 mg/m2 (135 mg/m2 for patients with prior pelvic radiation), given as a 24-hour continuous intravenous infusion every 3 weeks; dose adjustments allowed (escalations to 200 mg/m2 and deescalations to 110 mg/m2).
Number of subjects: 52
Study: 1496731

Group type: EXPERIMENTAL
Intervention: 5.1-[NANP]19 vaccine (50 or 400 micrograms doses)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Challenge with mosquitoes infected with P. falciparum
Number of subjects: 13
Study: 2988774

Group type: EXPERIMENTAL
Intervention: Piperazinedione (PZD)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Yoshi-864
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Razoxane (ICRF-159)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Lomustine (CCNU)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: ICRF-159 (in previously untreated patients)
Number of subjects: 127
Study: 30063397

Group type: EXPERIMENTAL
Intervention: 40-kV virtual monoenergetic imaging
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Iodine overlay imaging
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: 120-kV simulated imaging
Number of subjects: 209
Study: 27334739

Group type: EXPERIMENTAL
Intervention: UMEC 62.5 mcg added to ICS/LABA
Number of subjects: 236

Group type: COMPARATOR
Intervention: PBO added to ICS/LABA
Number of subjects: 236
Study: 22712527

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control exercise
Number of subjects: 8
Study: 22321218

Group type: EXPERIMENTAL
Intervention: Liver transplanted patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 20
Study: 20638515

Group type: EXPERIMENTAL
Intervention: Open appendectomy
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Combined open and laparoscopic patients
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Concordant complicated appendicitis
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Discordant complicated appendicitis
Number of subjects: 255
Study: 18381467

Group type: EXPERIMENTAL
Intervention: Self-report of colonoscopy (COL)
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Self-report of fecal occult blood test (FOBT)
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Self-report of sigmoidoscopy (SIG)
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Self-report of barium enema (BE)
Number of subjects: 857
Study: 17660155

Group type: EXPERIMENTAL
Intervention: Splint (exercises given 3 weeks postoperatively)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bulky bandage (exercises provided immediately)
Number of subjects: 40
Study: 15384889

Group type: EXPERIMENTAL
Intervention: Food inducing anti-secretory factor (AF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group food without AF-inducing properties
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mothers with mastitis (experimental group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mothers without mastitis (experimental group)
Number of subjects: 40
Study: 11274092

Group type: EXPERIMENTAL
Intervention: Frequency-Doubling Perimetry (FDP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Humphrey Field Analyzer (HFA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Test durations for FDP
Number of subjects: 60

Group type: COMPARATOR
Intervention: Test durations for HFA
Number of subjects: 60
Study: 9412308

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 1829
Study: 12959271

Group type: EXPERIMENTAL
Intervention: Remikiren 200 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Remikiren 300 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Remikiren 600 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Remikiren 800 mg
Number of subjects: 144

Group type: COMPARATOR
Intervention: Remikiren (various doses)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Remikiren
Number of subjects: 144
Study: 2882766

Group type: EXPERIMENTAL
Intervention: Temazepam 0.5, 1.0 and 1.5 mg kg‐1 in an elixir formulation
Number of subjects: 220

Group type: COMPARATOR
Intervention: Trimeprazine tartrate 3 mg kg‐1 in a syrup
Number of subjects: 220
Study: 31464933

Group type: EXPERIMENTAL
Intervention: Acupuncture in combination with prokinetic drugs
Number of subjects: 28

Group type: COMPARATOR
Intervention: Routine ICU treatment (Control)
Number of subjects: 28
Study: 28669169

Group type: EXPERIMENTAL
Intervention: Stage III breast cancer at diagnosis
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Rural residence
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Age, tumor size, tumor grade at diagnosis, hormone receptor status of estrogen and progesterone, Her-2
Number of subjects: 600
Study: 26860019

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg intravenous 10 min before surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (normal saline equivalent volume 30 min before surgery)
Number of subjects: 60
Study: 23334615

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 15
Study: 21732218

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (0.625 mg/day of conjugated equine estrogens)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 19660039

Group type: EXPERIMENTAL
Intervention: Prognostic information based on baseline wound characteristics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prognostic information based on 4-week wound characteristics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prognostic information based on 4-week characteristics for diabetic neuropathic foot ulcers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no prognostic information)
Number of subjects: 0
Study: 16504633

Group type: EXPERIMENTAL
Intervention: Cangrelor (4 microg/kg per minute)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399

Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 399
Study: 14705155

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa treatment study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bulimia nervosa studies
Number of subjects: 0
Study: 11194932

Group type: EXPERIMENTAL
Intervention: Insulin suppression test modified with octreotide
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 45
Study: 9315153

Group type: EXPERIMENTAL
Intervention: Transvaginal sonohysterography
Number of subjects: 29

Group type: COMPARATOR
Intervention: Transvaginal sonography
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Curettage
Number of subjects: 29
Study: 8325299

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (500 micrograms)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3098417

Group type: EXPERIMENTAL
Intervention: 6-hour iv infusion of recombinant interferon-gamma (rIFN-gamma) at doses ranging from 0.016 to 0.65 mg/m2/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 24-hour iv infusion of recombinant interferon-gamma (rIFN-gamma) at doses ranging from 0.01 to 0.05 mg/m2/day
Number of subjects: 62
Study: 30055991

Group type: EXPERIMENTAL
Intervention: Bilateral erector spinae plane (ESP) block with 3 mg/kg of 0.375% ropivacaine before anesthesia induction
Number of subjects: 106

Group type: COMPARATOR
Intervention: Paracetamol (1 gm every 6 hours) and tramadol (50 mg every 8 hours) intravenously
Number of subjects: 106
Study: 30527177

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 820

Group type: COMPARATOR
Intervention: Platinum-pemetrexed (intravenous every 3 weeks for up to six cycles)
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Rare EGFR mutations
Number of subjects: 820
Study: 27150079

Group type: EXPERIMENTAL
Intervention: Diazepam administration (7-8 days)
Number of subjects: 36
Study: 25082564

Group type: EXPERIMENTAL
Intervention: pemetrexed 500mg/m2 + cisplatin 75mg/m2 (PC)
Number of subjects: 256

Group type: COMPARATOR
Intervention: gemcitabine 1250mg/m2 + cisplatin 75mg/m2 (GC)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: pemetrexed/cisplatin (PC)
Number of subjects: 256

Group type: COMPARATOR
Intervention: gemcitabine/cisplatin (GC)
Number of subjects: 256
Study: 22386799

Group type: EXPERIMENTAL
Intervention: Life Goals Collaborative Care (LGCC)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 134
Study: 20595307

Group type: EXPERIMENTAL
Intervention: ITPA tool
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 145
Study: 17803897

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16121971

Group type: EXPERIMENTAL
Intervention: 5 million implanted cells
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 million implanted cells
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (rehabilitation only)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Action Research Arm Test
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Stroke Impact Scale
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Everyday Memory test
Number of subjects: 18
Study: 11688103

Group type: EXPERIMENTAL
Intervention: New method (N)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Traditional method (T)
Number of subjects: 84
Study: 9529807

Group type: EXPERIMENTAL
Intervention: Bonded amalgam sealants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resin-based pit and fissure sealants
Number of subjects: 0
Study: 7848898

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous nitroglycerin infusion for the first 48 hours after acute MI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged therapy with nitrates spanning the healing phase of acute anterior Q-wave MI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term nitrate therapy in patients with suspected MI
Number of subjects: 0
Study: 3396474

Group type: EXPERIMENTAL
Intervention: Single-dose cefotaxime (1g)
Number of subjects: 1950
Study: 29794563

Group type: EXPERIMENTAL
Intervention: Continuous sciatic nerve blockade with 5 ml/h ropivacaine 0.2% (CO)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single injection sciatic nerve blockade with 5 ml/h saline infusion (SIN)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Continuous sciatic nerve blockade (CO)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single injection sciatic nerve blockade (SIN)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 26568249

Group type: EXPERIMENTAL
Intervention: Grape Seed Extract (GSE) 300 mg/d (150 mg twice daily) for 6 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (0 mg GSE) for 6 weeks
Number of subjects: 36
Study: 25870665

Group type: EXPERIMENTAL
Intervention: Intravitreal administration of triamcinolone acetonide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravitreal administration of triamcinolone acetonide in combination with bevacizumab
Number of subjects: 0
Study: 22445441

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Doubling of statin dose
Number of subjects: 63
Study: 20491720

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy for psychosis (CBTp)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 74
Study: 18949295

Group type: EXPERIMENTAL
Intervention: Ca(OH)2 + saline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ca(OH)2 + 2% chlorhexidine gluconate (CHX) gel
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 15
Study: 16181937

Group type: EXPERIMENTAL
Intervention: Manipulation intervention
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Stabilization exercise intervention
Number of subjects: 131
Study: 12182236

Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg orally)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 10
Study: 11009276

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 150
Study: 8776184

Group type: EXPERIMENTAL
Intervention: Autotransfusion without heparin-bonded circuit (Group 2)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Autotransfusion with heparin-bonded circuit (Group 3)
Number of subjects: 105

Group type: COMPARATOR
Intervention: No autotransfusion (Group 1)
Number of subjects: 105
Study: 1632172

Group type: EXPERIMENTAL
Intervention: Vf of 50 ml.kg‐1.min‐1 (Group 1)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vf of 75 ml.kg‐1.min‐1 (Group 2)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vf of 100 ml.kg‐1.min‐1 (Group 3)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vf of 100 ml.kg‐1.min‐1 for 15 min, 75 ml.kg‐1.min‐1 for the next 15 min and 50 ml.kg‐1.min‐1 thereafter (Group 4)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vf of 25 ml.kg‐1.min‐1 for 10 min and switched off for the remainder of the procedure (Group 5)
Number of subjects: 46
Study: 6432173

Group type: EXPERIMENTAL
Intervention: Lateral subcutaneous sphincterotomy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Anal dilatation
Number of subjects: 58
Study: 31764105

Group type: EXPERIMENTAL
Intervention: ZDV-based ART
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: TDF-based ART
Number of subjects: 720

Group type: COMPARATOR
Intervention: ZDV alone
Number of subjects: 720
Study: 29684771

Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation at a daily dose of 30 mg for 100 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation at a daily dose of 60 mg for 100 days
Number of subjects: 90
Study: 26590366

Group type: EXPERIMENTAL
Intervention: Export®
Number of subjects: 185

Group type: COMPARATOR
Intervention: Angiojet®
Number of subjects: 185
Study: 24290594

Group type: EXPERIMENTAL
Intervention: Yeast hydrolysate 1 g/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo 1 g/d
Number of subjects: 0